These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 2225567)

  • 1. Immunotherapy of the rat 13762SC mammary adenocarcinoma by vaccinia virus augmentation of tumor immunity.
    Archer TP; Bretscher P; Ziola B
    Clin Exp Metastasis; 1990; 8(6):519-32. PubMed ID: 2225567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy of an established rat mammary adenocarcinoma (13762A) with intratumor injection of Corynebacterium parvum.
    Kreider JW; Bartlett GL; Purnell DM; Webb S
    Cancer Res; 1978 Mar; 38(3):689-92. PubMed ID: 626972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic adoptive transfer of immunity to 13762A rat mammary adenocarcinoma.
    Boyer CM; Kreider JW; Bartlett GL
    Cancer Res; 1981 Jun; 41(6):2394-400. PubMed ID: 6972251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased immunogenicity of a spontaneous variant clone of the 13762A rat mammary adenocarcinoma.
    Kreider JW; Bartlett GL
    J Natl Cancer Inst; 1985 Jul; 75(1):141-9. PubMed ID: 3859687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishment of tumor-specific immunotherapy model utilizing vaccinia virus-reactive helper T cell activity.
    Shimizu Y; Hasumi K; Masubuchi K; Okudaira Y
    Eur J Immunol; 1988 Nov; 18(11):1773-8. PubMed ID: 2974424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experimental cancer immunotherapy: comparison of tumor rejection if F344 rats given live Mycobacterium bovis (Strain BCG) and killed Corynebacterium parvum.
    Likhite VV
    J Natl Cancer Inst; 1976 May; 56(5):985-9. PubMed ID: 994209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rat adenocarcinoma 13762 expresses tumor rejection antigens but tumor-bearing animals exhibit tumor-specific immunosuppression.
    Frey AB; Appleman LJ
    Clin Immunol Immunopathol; 1993 Nov; 69(2):223-33. PubMed ID: 8403560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune response to a syngeneic mammary adenocarcinoma. III. Development of memory and suppressor functions modulating cellular cytotoxicity.
    Kuperman O; Fortner GW; Lucas ZJ
    J Immunol; 1975 Nov; 115(5):1282-7. PubMed ID: 1176776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rejection of tumors and metastases in Fischer 344 rats following intratumor administration of killed Corynebacterium parvum.
    Likhite VV
    Int J Cancer; 1974 Nov; 14(5):684-90. PubMed ID: 4459281
    [No Abstract]   [Full Text] [Related]  

  • 10. Suitability of rat mammary adenocarcinoma 13762 as a model for BCG immunotherapy.
    Kreider JW; Bartlett GL; Purnell DM
    J Natl Cancer Inst; 1976 Apr; 56(4):797-802. PubMed ID: 815563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conditions for effective Bacillus Calmette-Guérin immunotherapy of postsurgical metastases of 13762A rat mammary adenocarcinoma.
    Kreider JW; Bartlett GL; Boyer CM; Purnell DM
    Cancer Res; 1979 Mar; 39(3):987-92. PubMed ID: 427785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induced antitumor immunity against DMBA-4 metastatic mammary tumors in rats using laser immunotherapy.
    Chen WR; Jeong SW; Lucroy MD; Wolf RF; Howard EW; Liu H; Nordquist RE
    Int J Cancer; 2003 Dec; 107(6):1053-7. PubMed ID: 14601069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic adoptive transfer of immunity and low-dose irradiation eradicate metastases of 13762A rat mammary adenocarcinoma.
    Kreider JW; Bartlett GL; Christensen ND; Welsh P
    Int J Cancer; 1985 Aug; 36(2):217-24. PubMed ID: 3160672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune response to a syngeneic mammary adenocarcinoma. I. Comparison of kinetics of tumor cell growth and cytotoxic responses in syngeneic and allogeneic rats.
    Fortner GW; Kuperman O; Lucas ZJ
    J Immunol; 1975 Nov; 115(5):1269-76. PubMed ID: 1080776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Significance of priming of hosts with virus in the tumor-specific immunotherapy model utilizing virus-reactive helper T cell activity].
    Shimizu Y; Hasumi K; Masubuchi K; Okudaira Y
    Nihon Gan Chiryo Gakkai Shi; 1989 May; 24(5):1007-14. PubMed ID: 2528599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy of tumor-bearing mice utilizing virus help.
    Shimizu Y; Hasumi K; Masubuchi K; Okudaira Y
    Cancer Immunol Immunother; 1988; 27(3):223-7. PubMed ID: 3263207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rejection of mammary adenocarcinoma cell tumors and the prevention of progressive growth of incipient metastases following intratumor permeation with killed Bordetella pertussis.
    Likhite VV
    Cancer Res; 1974 Oct; 34(10):2790-4. PubMed ID: 4370327
    [No Abstract]   [Full Text] [Related]  

  • 18. Feasibility of UV-inactivated vaccinia virus in the modification of tumor cells for augmentation of their immunogenicity.
    Wakamiya N; Wang YL; Imai H; Gu HX; Ueda S; Kato S
    Cancer Immunol Immunother; 1986; 23(2):125-9. PubMed ID: 3779714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of immunity in mice cured of primary/metastatic growth of EMT6 or 4THM breast cancer by chemotherapy or immunotherapy.
    Gorczynski RM; Chen Z; Erin N; Khatri I; Podnos A
    PLoS One; 2014; 9(11):e113597. PubMed ID: 25409195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Destruction of regional lymph node metastases of rat mammary adenocarcinoma 13762A by treatment with Corynebacterium parvum.
    Kreider JW; Bartlett GL; Purnell DM; Webb S
    Cancer Res; 1978 Dec; 38(12):4522-6. PubMed ID: 719637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.